Search Results Search Sort by RelevanceMost Recent State of the Art and Science Sep 2005 Approach to the Patient with Alcoholic Liver Disease Howard J. Worman, MD An overview of alcoholic liver disease and the process of diagnosing and treating it. Virtual Mentor. 2005;7(9):600-603. doi: 10.1001/virtualmentor.2005.7.9.cprl1-0509. Viewpoint Nov 2005 Steroid Hysteria: Unpacking the Claims Norman Fost, MD, MPH A physician argues in favor of the use of performance-enhancing substances by adult participants in sports. Virtual Mentor. 2005;7(11):767-769. doi: 10.1001/virtualmentor.2005.7.11.oped2-0511. Viewpoint Nov 2005 Medical Ethics and Performance-Enhancing Drugs Carlos R. Hamilton, MD A physician's role in controlling the abuse of performance-enhancing drugs includes educating patients about the harms associated with these drugs and encouraging them to adopt safe and appropriate training programs. Virtual Mentor. 2005;7(11):764-766. doi: 10.1001/virtualmentor.2005.7.11.oped1-0511. Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408. In the Literature Aug 2004 Ethical Issues in the Application and Prescription of CNS Interventions Abraham P. Schwab, PhD A neuroscientist and a sociologist discuss the ethical concerns with common neurological medicines that are used to enhance or change behavior. Virtual Mentor. 2004;6(8):347-349. doi: 10.1001/virtualmentor.2004.6.8.jdsc1-0408. Medicine and Society Jul 2024 What Would Equitable Harm Reduction Look Like? Oluwole Jegede, MD, MPH, Julio C. Nunes, MD, Terence Tumenta, MD, MPH, Carmen Black, MD, and Joao P. DeAquino, MD Structural determinants of health frameworks must be person centered and express antiracism to be effective. AMA J Ethics. 2024;26(7):E572-579. doi: 10.1001/amajethics.2024.572. Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562. Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551. Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512. Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520. Pagination First page « First Previous page ‹ Previous … Page 11 Page 12 Page 13 Page 14 Current page 15 Page 16 Page 17 Page 18 Page 19 Next page Next › Last page Last »
State of the Art and Science Sep 2005 Approach to the Patient with Alcoholic Liver Disease Howard J. Worman, MD An overview of alcoholic liver disease and the process of diagnosing and treating it. Virtual Mentor. 2005;7(9):600-603. doi: 10.1001/virtualmentor.2005.7.9.cprl1-0509.
Viewpoint Nov 2005 Steroid Hysteria: Unpacking the Claims Norman Fost, MD, MPH A physician argues in favor of the use of performance-enhancing substances by adult participants in sports. Virtual Mentor. 2005;7(11):767-769. doi: 10.1001/virtualmentor.2005.7.11.oped2-0511.
Viewpoint Nov 2005 Medical Ethics and Performance-Enhancing Drugs Carlos R. Hamilton, MD A physician's role in controlling the abuse of performance-enhancing drugs includes educating patients about the harms associated with these drugs and encouraging them to adopt safe and appropriate training programs. Virtual Mentor. 2005;7(11):764-766. doi: 10.1001/virtualmentor.2005.7.11.oped1-0511.
Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408.
In the Literature Aug 2004 Ethical Issues in the Application and Prescription of CNS Interventions Abraham P. Schwab, PhD A neuroscientist and a sociologist discuss the ethical concerns with common neurological medicines that are used to enhance or change behavior. Virtual Mentor. 2004;6(8):347-349. doi: 10.1001/virtualmentor.2004.6.8.jdsc1-0408.
Medicine and Society Jul 2024 What Would Equitable Harm Reduction Look Like? Oluwole Jegede, MD, MPH, Julio C. Nunes, MD, Terence Tumenta, MD, MPH, Carmen Black, MD, and Joao P. DeAquino, MD Structural determinants of health frameworks must be person centered and express antiracism to be effective. AMA J Ethics. 2024;26(7):E572-579. doi: 10.1001/amajethics.2024.572.
Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562.
Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551.
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512.
Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520.